Eosinophilia is an expansion of eosinophil numbers in the blood, due to either a reactive process, such as an allergic reaction or parasitic infection (secondary eosinophilia), or to a neoplastic process that involves clonal eosinophils or their precursors (primary eosinophilia). The eosinophil has potent proinflammatory, prothrombotic, and profibrotic activities. Eosinophilia can accompany a range of disorders from benign diseases, to eosinophilias with organ damage, to eosinophil neoplasms. Given the broad array of diseases associated with eosinophilia, a variety of presentations may prompt testing. The extent of peripheral blood eosinophilia (>500 or >1,500 cells/µL) and the impact of eosinophilia on major organs should be evaluated. Identifying the etiology is essential for treatment decisions, and treating the underlying disorder often will resolve the eosinophilia. In addition to the laboratory tests described below, histopathologic analysis of a tissue biopsy from a relevant site and/or a bone marrow biopsy may be necessary for diagnosis.
Quick Answers for Clinicians
Patients with eosinophilia discovered during medical evaluations by blood testing or in tissue biopsy, or those with suspicion of eosinophilia based on clinical findings such as rash (particularly with urticarial/edema, pruritus, eczema, blisters) or signs suggestive of systemic illness, should be tested. Cutaneous involvement is a common presenting clinical manifestation.
An initial workup involves a CBC with differential and peripheral blood smear analysis, and then screening for secondary causes (clinically driven testing). Reactive (secondary) eosinophilias are most common, and histopathologic examination of a tissue biopsy may be important for defining the condition. If primary eosinophilia remains likely, then the next steps are histopathologic analysis of a bone marrow biopsy and cytogenetic analysis.
A broad range of conditions can result in secondary/reactive eosinophilia. The workup should be clinically driven to determine cause and should take into account the magnitude of peripheral blood eosinophilia and the effect of eosinophilia on major organs. Due to risks associated with the hyperinfection syndrome, consider testing patients for Strongyloides (Strongyloides immunoglobulin G [IgG] antibody testing) before glucocorticoid administration. Workup for primary/neoplastic eosinophilia should be pursued when secondary/reactive eosinophilia has been ruled out, or if indicated by hematologic signs, such as cytopenias or abnormal blood smear, and/or other specific signs or symptoms, such as fever or mucosal ulcers.
The presentation and evaluation of eosinophilia may be similar across age groups (children, adolescents, and adults). Allergies and asthma commonly present in childhood. Food allergies and eosinophilic esophagitis may present with vomiting as a symptom (clinical symptoms of eosinophilic esophagitis vary with age). Eosinophilia accompanying immunodeficiency commonly presents in infancy.
Monitoring should include assessment for possible end-organ damage because any organ system can be affected by persistent eosinophilia. Monitoring patients for thromboembolic phenomena and cardiac disease (eg, splinter hemorrhages, nail fold infarcts, and cardiac murmur) is also critical because these conditions can be associated with eosinophilia from any cause.
Indications for Testing
Peripheral blood eosinophilia may be discovered during a screening evaluation or workup for specific symptoms. Patient history (eg, medical or travel history, environmental exposure, drugs) should guide further evaluation.
|Peripheral Blood Eosinophiliaa||Counts/µL of Blood|
|Hypereosinophilia||>1,500 recorded on ≥2 determinations with minimum interval of 4 wks (unless immediate designation is required to initiate therapy because of eosinophil-related organ dysfunction)|
|Normal level of eosinophils||50-500 (1-6% of WBC count range)|
|Percentage of eosinophils exceeds 20% of all nucleated bone marrow cells and/or histopathologic findings reveal extensive eosinophil infiltration or activation/degranulation|
|aThe World Health Organization classifies peripheral blood eosinophilia as 1 of 3 levels: mild, with an AEC from the upper limit of normal to 1,500/µL; moderate, with an AEC 1,500–5,000/µL; or severe, with an AEC >5,000/µL.
AEC, absolute eosinophil count; WBC, white blood cell
First-level characterization of a possible eosinophil-related disorder involves a CBC with differential to determine AEC and the percentage of eosinophils within the WBC population. Repeat testing may be indicated for eosinophilia (typically considered >500 cells/µL) but may not be required if absolute counts exceed 1,500 cells/µL, especially in a symptomatic patient (anemia and thrombocytopenia detected on CBC may indicate a neoplasm).
A peripheral blood smear analysis by a hematopathologist can be used to assess eosinophils for abnormal granulation, nuclear segmentation, or size. Abnormal eosinophils may indicate a neoplasm, although abnormalities also can be observed in reactive processes. Abnormalities in other cell lines may contribute to diagnosis.
To identify eosinophil involvement in tissue, especially when eosinophil degranulation may have occurred and intact eosinophils are not identifiable, consider staining for eosinophil granule major basic protein 1 (eMBP1) or another eosinophil-specific marker. Eosinophil granule proteins, including eMBP1, have various and numerous toxic effects on tissues and organs, and their detection has important pathophysiologic and treatment implications.
Testing for Secondary/Reactive Eosinophilia
A broad range of conditions can result in secondary/reactive eosinophilia, and a clinically driven workup is needed to determine cause. Conditions commonly associated with eosinophilia include drug reactions, allergy/asthma, hypersensitivity conditions, pulmonary eosinophilic diseases, skin diseases, metabolic conditions, and infections (especially parasitic). Nonmyeloid leukemias also can be implicated. Additional rare conditions include Gleich syndrome and familial eosinophilia. Due to risks associated with hyperinfection syndrome, consider testing all patients for Strongyloides (Strongyloides immunoglobulin G [IgG] antibody testing) before glucocorticoid administration.
See Additional Testing below.
Once secondary causes have been ruled out, consider a tissue and/or bone marrow biopsy, as applicable. Assessment for a possible acute or chronic myeloid or lymphoproliferative disorder may involve the following , :
- Morphologic examination of the blood and bone marrow by histopathology and immunohistochemistry
- Fluorescence in situ hybridization (FISH)
- Flow immunocytometry
- T-cell clonality evaluation
A workup for a patient with eosinophilia may involve a range of other tests, based on history and physical findings. These might include:
- Inflammatory, infectious, and immunologic marker tests, such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), antiproteinase 3 and antimyeloperoxidase (c-ANCA and p-ANCA), IgE level, other parasite serologies (in addition to Strongyloides), fungal or viral serologies (HIV, human T-cell leukemia-lymphoma virus), interleukin-5
- Metabolic marker tests, such as liver function tests (including aspartate aminotransferase and alanine aminotransferase), renal function tests (including creatinine, blood urea nitrogen [BUN], and urinalysis for protein and sediment), B12 serum level, mast cell/basophil tryptase level, Beta-2 (β2) microglobulin, lactate dehydrogenase, coagulation factors, troponin (before imatinib treatment), angiotensin-converting enzyme, thyroid and adrenal function tests
- Serum protein analyses, such as serum protein electrophoresis, quantitative immunoglobulins, IgG4 subclass level, and immunofixation electrophoresis for monoclonal proteins
- Cytogenetic testing (see Hematopathologic Assessment above) to assess for specific chromosomal abnormalities such as FIP1L1-PDGFRA deletion or BCR-ABL1, JAK2 V617F, KIT D816V, or FGFR1 mutations, PDGFRA/PDGFRB rearrangements
- Assessment for T-cell receptor gene rearrangement
Monitoring should include assessment for possible end-organ damage because any organ system can be affected by persistent eosinophilia. , Physical examination as part of monitoring should include assessment for lymphadenopathy and organomegaly, observation for splinter hemorrhages and nail fold infarcts as indicators of thromboembolic phenomenon, and cardiac auscultation to detect murmurs associated with endomyocardial disease. Test selection is clinically driven and also may include imaging and other testing (such as electrocardiogram or pulmonary function tests).
ARUP Laboratory Tests
Indirect Immunofluorescence (IIF)
Diagnose Strongyloides infection
Semi-Quantitative Enzyme-Linked Immunosorbent Assay
Aid in diagnosis and classification of hematopoietic neoplasms accompanied by prominent eosinophilia
Fluorescence in situ Hybridization (FISH)
Aid in evaluation of hematopoietic neoplasms (eg, leukemia, lymphoma)
Aid in diagnosis of T-cell lymphoproliferative disorders
Aid in diagnosis of IgG4-related disease, often accompanied by peripheral blood and/or tissue eosinophilia
For additional information, refer to IgG4-Related Disease Consult Topic
Use in the evaluation of individuals with skin or mucous membrane symptoms and/or lesions with peripheral blood or tissue eosinophilia
For more information, see the ARUP Immunobullous Disease Testing Comparison table
Semi-Quantitative Indirect Immunofluorescence (IIF)/Semi-Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)
Components: BMZ antibodies, IgG by IIF; BMZ antibodies, IgA by IIF; BP180 and BP230 antibodies, IgG by ELISA; collagen type VII antibodies, IgG by ELISA; cell surface antibodies, IgG by IIF; desmoglein 1 and 3 antibodies, IgG by ELISA; cell surface antibodies, IgA by IIF
Semi-Quantitative Indirect Immunofluorescence (IIF)/Semi-Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)
Components: BMZ antibodies, IgG by IIF; BMZ antibodies, IgA by IIF; BP180 and BP230 antibodies, IgG by ELISA; collagen type VII antibodies, IgG by ELISA
Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607-612.e9.
Gotlib J. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92(11):1243-1259.
Montgomery ND, Dunphy CH, Mooberry M, et al. Diagnostic complexities of eosinophilia. Arch Pathol Lab Med. 2013;137(2):259-269.
Leiferman KM, Peters MS. Eosinophil-related disease and the skin. J Allergy Clin Immunol Pract. 2018;6(5):1462-1482.e6.
Ghosh K, Ghosh K. Strongyloides stercoralis septicaemia following steroid therapy for eosinophilia: report of three cases. Trans R Soc Trop Med Hyg. 2007;101(11):1163-65.
Marcos LA, Terashima A, DuPont HL, et al. Strongyloides hyperinfection syndrome: an emerging global infectious disease. Trans R Soc Trop Med Hyg. 2008;102(4):314-318.
Chen JW, Kao JY. Eosinophilic esophagitis: update on management and controversies. BMJ. 2017;359:j4482.
Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: Proceedings of the AGREE conference. Gastroenterology. 2018;155(4):1022-1033.e10.
Butt NM, Lambert J, Ali S, et al. Guideline for the investigation and management of eosinophilia. Br J Haematol. 2017;176(4):553-572.
Bain BJ, Ahmad S. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol. 2014;166(6):809-817.
Mejia R, Nutman TB. Evaluation and differential diagnosis of marked, persistent eosinophilia. Semin Hematol. 2012;49(2):149-159.
Bochner BS, Book W, Busse WW , et al. Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD). J Allergy Clin Immunol. 2012;130(3):587-596.
Bochner BS. The eosinophil: For better or worse, in sickness and in health. Ann Allergy Asthma Immunol. 2018;121(2):150-155.
Borrego L, Maynard B, Peterson EA, et al. Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins. Am J Pathol. 1996;148(3):897-909.
Butterfield JH, Leiferman KM, Abrams J, et al. Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood. 1992;79(3):688-692.
Diny NL, Rose NR, Ciháková D. Eosinophils in autoimmune diseases. Front Immunol. 2017;8:484.
Drage LA, Davis MDP, De Castro F, et al. Evidence for pathogenic involvement of eosinophils and neutrophils in Churg-Strauss syndrome. J Am Acad Dermatol. 2002;47(2):209-216.
Gleich GJ, Klion AD, Lee JJ, et al. The consequences of not having eosinophils. Allergy. 2013;68(7):829-835.
Gleich GJ, Leiferman KM. The hypereosinophilic syndromes: current concepts and treatments. Br J Haematol. 2009;145(3):271-285.
Hujoel IA, Jaeger TM. 65-year-old woman with chronic eosinophilia. Mayo Clin Proc. 2018;93(5):646-650.
Jinnin M, Yamamoto T, Asano Y, et al. Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis. J Dermatol. 2018;45(8):881-890.
Khoury P, Akuthota P, Ackerman SJ, et al. Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD). J Leukoc Biol. 2018;104(1):69-83.
Khoury P, Makiya M, Klion AD. Clinical and biological markers in hypereosinophilic syndromes. Front Med (Lausanne). 2017;4:240.
Larsen RL, Savage NM. How I investigate eosinophilia. Int J Lab Hematol. 2019;41(2):153-161.
Fitzpatrick’s Dermatology in General Medicine - Regulation of the Production and Activation of Eosinophils, Ch 31
Leiferman K, Beck L, Gleich G. Chapter 31: regulation of the production and activation of eosinophils. In: Goldsmith LA, Katz SI, Gilchrest BA, et al, eds. Fitzpatrick’s Dermatology in General Medicine. 8th ed. McGraw-Hill Medical; 2012.
Leiferman K, Peters M. Chapter 36: eosinophils in cutaneous diseases. In: Goldsmith LA, Katz SI, Gilchrest BA, et al, eds. Fitzpatrick’s Dermatology in General Medicine. 8th ed. McGraw-Hill Medical; 2012.
Dermatological Signs of Systemic Disease - Eosinophil-associated diseases with dermatologic manifestations.
Leiferman KM, Peters M. Eosinophil-associated dermatoses. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 1st ed. Mosby; 2003
Leiferman KM. Eosinophil-associated diseases with dermatologic manifestations. In: Callen JP, Jorizzo JL, Zone JJ, et al, eds. Dermatological Signs of Systemic Disease. 5th ed. Elsevier; 2016.
McBrien CN, Menzies-Gow A. The biology of eosinophils and their role in asthma. Front Med (Lausanne). 2017;4:93.
Musette P, Janela B. New insights into drug reaction with eosinophilia and systemic symptoms pathophysiology. Front Med (Lausanne). 2017;4:179.
Navabi B, Upton JE. Primary immunodeficiencies associated with eosinophilia. Allergy Asthma Clin Immunol. 2016;12:27.
Nhu QM, Aceves SS. Tissue remodeling in chronic eosinophilic esophageal inflammation: parallels in asthma and therapeutic perspectives. Front Med (Lausanne). 2017;4:128.
Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124(6):1319-1325.e3.
Soria A, Bernier C, Veyrac G, et al. Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: a retrospective study. J Am Acad Dermatol. 2019;82(3):606-611.
Valent P, Gleich GJ, Reiter A , et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol. 2012;5(2):157-176.
Vega F, Medeiros J, Bueso-Ramos CE, et al. Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. Am J Clin Pathol. 2015;144(3):377-392.
Wright BL, Leiferman KM, Gleich GJ. Eosinophil granule protein localization in eosinophilic endomyocardial disease. N Engl J Med. 2011;365(2):187-188.